newsfilter
← Latest News
Business Wire·

Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results

– Third Quarter 2023 Total Revenue of $43.3 Million; Net Product Revenue for QINLOCK® (ripretinib) Increased 29% to $41.8 Million Compared to Third Quarter 2022 – – Announced Positive Top-line Results for MOTION